Navigation Links
DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
Date:1/30/2008

New features reduce trial delivery time and ensure faster access to client

data

CLEVELAND, Jan. 30 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported it is increasing options, flexibility and efficiency for end-users with the DATATRAK eClinical(TM) 2008 Q1 Release.
Some of the new interactive features and modules include:

-- Trial Manager

New trial management workflows empower virtual teams to setup, design,

test, approve and deploy clinical trials through a web browser.

Building the foundation for a better CTMS, new enterprise consoles now

track performance metrics across a sponsor's drug programs.

-- VisualArchitect(TM)

Trial design goes to the next level with a new Zero Footprint, drag-

and-drop interface -- ensuring faster and more efficient trial design.

Accessible from Trial Manager, the new VisualArchitect(TM) allows trial

designers to quickly manipulate the layout and features of a clinical

trial with access to robust libraries of forms and client-specific

configurations.

-- Manager Performance Enhancements

DATATRAK eClinical is more efficient than ever in displaying data,

giving managers an improved interface with increased functionality for

sorting, filtering and exporting data. This translates into performance

enhancements and even faster turn-around times for day-to-day tasks.

-- eTrain

New online training for end-users is now available with eTrain for Data

Collection and Investigator Review and eSignature. Users can access

through a new Learning Management System (LMS). A "My Training" link on

the study homepage takes the user directly into the LMS to begin self-

paced, web-based training.

-- Help Center

Online Help is just a click away. User-driven access to product

manuals, release notes, Frequently Asked Questions, demonstrations and

other eClinical information is available 24x7 -- world-wide.

-- Lab Import Improvements

DATATRAK's enhanced system increases the efficiency of uploading lab

imports, processes the data, provides a detailed report and stores all

logs and discrepancies -- behind the scenes -- freeing up time to

manage other tasks.

-- Reporting and Export Enhancements

Create "Report Packages" or custom exports by combining multiple

reports in one output file or zip file. Add more detail to the

standard exports, too, with the path and visit for each data set. For

Queries, Alerts, Comments, and Audit Trails we've added visit, path,

parent form, and question title.

-- Audit Trail Enhancements

The audits trail is more comprehensive than ever, now displaying

information like SDV, Lock, and PI Signature status, saving time when

researching user activities.

"We are very pleased to offer these new enhancements in our eClinical software," said Jim Bob Ward, Executive Vice President, Research and Development, DATATRAK International. "This is a compliment to the Product Advisory Council; their contribution has ensured these new features and functionality provide a wide range of efficiencies and cost-savings for anyone within the clinical trial spectrum."

"This global market is definitely moving towards an eClinical set of offerings for clinical trials," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "Most providers attempt to piece together such a complete set of capabilities by integrating multiple unrelated products in order to satisfy increasing client demands. The DATATRAK eClinical Platform houses all of these capabilities under one unified database and user interface, eliminating the significant validation and logistical challenges of integration efforts from multiple providers."

DATATRAK eClinical Version 5.0 is now available. For additional information please visit the company's website at http://www.datatrak.net or contact marketing@datatrak.net.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 17 drugs and devices that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereo Mammography Takes Breast Imaging to a New Dimension
2. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
3. VA National Campaign Takes Aim at Resistant Staph Infections
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
9. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
Breaking Medicine Technology:
(Date:4/29/2016)... Springs, California (PRWEB) , ... April 29, 2016 ... ... lies at the heart of our nation’s productivity, stability, even security. Most importantly, ... for their organizations. , Then why are American workers so unhappy? , Just ...
(Date:4/29/2016)... ... ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite Back Against ... breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers participated in ... 1-mile walk were held to increase awareness about Lyme disease and to raise funds ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one ... to improve smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering ... patients to learn more about the options currently available to them and which ones ...
Breaking Medicine News(10 mins):